The role of 2‐chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia

Treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) often constitutes a challenge for the clinical haematologist. Single‐ agent and combination chemotherapy have failed to increase the response rate or survival of patients with AILD. A total of seven patients wi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1999-01, Vol.104 (1), p.163-165
Main Authors: Sallah, Sabah, Wehbie, Robert, Lepera, Pamela, Sallah, Waddah, Bobzien, William
Format: Article
Language:English
Subjects:
2‐CdA
Adult
Aged
AILD
Antineoplastic agents
Biological and medical sciences
Blood Protein Disorders - drug therapy
Chemotherapy
Chronic Disease
Cladribine - therapeutic use
Female
Hematology
Humans
Immunoblastic Lymphadenopathy - drug therapy
Immunosuppressive Agents - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
purine analogues
Recurrence
Retrospective Studies
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) often constitutes a challenge for the clinical haematologist. Single‐ agent and combination chemotherapy have failed to increase the response rate or survival of patients with AILD. A total of seven patients with refractory or relapsed AILD were treated with 2‐chlorodeoxyadenosine (2‐CdA) for variable number of cycles. The overall response rate was 57% with two patients (28.5%) achieving complete and sustained response. 2‐Chlorodeoxyadenosine appears to be an active agent for patients with previously treated AILD. Phase II studies evaluating the efficacy of this agent as front‐line treatment for AILD are justified, especially in the absence of any effective therapy for this disorder.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1999.01139.x